ADVANCED HEPATOCELLULAR CARCINOMA

This early-phase study tests an experimental drug called ALN-BCAT, alone or with an immunotherapy (pembrolizumab), in people with advanced liver cancer that has spread. The drug targets a specific genetic change (WNT pathway mutation) found in some liver cancers. The main goals a…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination can slow or stop tumor growth better than cabozantinib alone. Ab…

This study tests a new three-drug combination (SHR-8068, adebrelimab, and bevacizumab) against standard two-drug treatments for advanced liver cancer that cannot be removed by surgery. About 590 adults with this type of cancer will participate. The goal is to see if the new combo…

This study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus precise, high-dose radiation (SBRT) to the liver tumor. The goal is to see if adding radiation helps patients live…

This study is for people with advanced liver cancer that has spread. It tests whether giving two immune-boosting drugs (durvalumab with or without tremelimumab) after a short course of radiation can help shrink tumors. About 21 participants will receive radiation followed by the …

This study tests whether adding celecoxib (a pain reliever) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The…

This study tests whether combining two drugs, ligufalimab and cadonilimab, can shrink tumors in people with advanced liver or bile duct cancers that no longer respond to standard treatments. About 64 adults will receive the drug combination to see if it improves response rates an…

This early-stage trial tests a new treatment called CNCT19, which uses a patient's own immune cells modified to attack cancer cells. It is for people with advanced liver cancer who cannot have surgery or other local treatments. The main goals are to check safety and find the best…

This study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…

This early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…

This early-phase trial tests a new drug called AU409 in people with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see what side effects occur. About 36 adults whose cancer has not responded to standard treatme…

This early-stage study tests a new drug, BGB-B2033, alone or with other medicines, in people with advanced liver, stomach, lung, or yolk sac cancers that have spread. The main goals are to check safety and find the right dose. About 140 participants will take part.

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…